Menu

Home / For Visitors / Exhibitor Product / Antithrombotic Drug with Low Risk of Bleeding

Antithrombotic Drug with Low Risk of Bleeding

Category:

Exhibitor: Center for Biomedical Research and Development

Booth No: N416

Characteristic

The current fibrinolytic therapy or percutaneous coronary intervention (PCI) needs to be combined with anti-platelet drugs for subsequent restenosis or recurrent thrombosis. Antithrombotic drugs in the market are associated with significant bleeding risk and thrombocytopenia. We now have successfully developed a novel antithrombotic drug without these side effects.

Other Products

Highest Rated Products

TOP